Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News

  News Archive

Predicting the Immune Systems Ability to Fight Tumors
Monday, April 18, 2016
Colorectal cancers heavily bedecked with tumor-related proteins called neoantigens are likely to be permeated with disease-fighting white blood cells.

Cancer Cells Turn Healthy Cells to the ‘Dark Side’
Monday, April 18, 2016
Cancer cells use a mutant gene to coerce neighbouring healthy tissue into helping with the disease’s growth and spread, a major new study reports.

Enzyme Link Between Excessive Heart Muscle Growth, Cancer Growth
Saturday, April 16, 2016
Researchers at UTSW have found that the drugs currently used to inhibit these enzymes in cancer may also be effective in treating enlargement of the heart muscle.

Epigenomics Receives FDA Approval for Epi proColon®
Saturday, April 16, 2016
Company has announced that the U.S. FDA has approved the Company’s lead product, Epi proColon®, blood-based colorectal cancer screening test.

Nanoparticles Deliver Anticancer Cluster Bombs
Saturday, April 16, 2016
Researchers at Emory have devised a triple-stage "cluster bomb" system for delivering the chemotherapy drug cisplatin, via tiny nanoparticles designed to break up when they reach a tumor.

QIAGEN, Mirati Therapeutics Announce Partnership
Friday, April 15, 2016
Company has announced a partnership with Mirati Therapeutics to develop novel companion diagnostics in lung cancer.

Agena, Horizon to Launch iPLEX® Reference Standards
Friday, April 15, 2016
Company has announced agreement with Horizon to launch iPLEX® reference standards to assess quality and performance of oncology-based assays on the MassARRAY System.

New Liquid Biopsy RAS Testing Available for Clinical Practices
Thursday, April 14, 2016
Company has announced that its OncoBEAM® RAS CRC test has been granted CE Mark approval.

UCSF Immunologist to Head New Parker Institute for Cancer Immunotherapy
Thursday, April 14, 2016
Renowned UC San Francisco immunologist Jeffrey Bluestone, PhD, has been named president and CEO of the Parker Institute for Cancer Immunotherapy, a national initiative launched with a $250 million grant from The Parker Foundation.

<< 5 6 7 8 9 10 11 >>
Showing Results 71 - 80 of 4098
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!